

DRUG ACCESS APARTHEID


Salomé Meyer

SOUTH AFRICA

TWO TIER HEALTH = most inequitable in world

For Cancer Services:

- Private sector service 16% of Population = 84% of Health Care Professionals
- Public sector service 84% of Population = 16% of Health Care Professionals



RESEARCH: PATENT BARRIERS OF CANCER MEDICINES

- Patent status and length
- Affordability
- Accessibility

= Patents block generic availability,
inequitable access for those who
need most, high pricing

24 CASE STUDY MEDICINES: ACCESSIBILITY

- 21 Medicines available in private sector
- 7 are available in the public sector
- 10 are on WHO Essential Medicines List
- ONLY 5 on SA EDL

Patent blocks equitable access and leads to excessive pricing



THE *Tobeka Doku* CAMPAIGN

CAMPAIGN FOR ACCESS TO TRASTUZUMAB

#fortobeka



www.canceralliance.co.za | www.fixthepatentlaws.org

TRASTUZUMAB 2018

ACCRUED SALES FOR 2017 = US\$ 88.2 BILLION

ORIGINATOR HERCEPTIN® = \$ 33 037

CLONE HERCLON® = \$ 9041

ESTIMATE BIOGENERIC/BIOSIMILAR = \$ 243

TRASTUZUMAB 2019

ORIGINATOR HERCEPTIN IV ® = \$ 22 770

CLONE HERCLON® = \$ 9041

SUBCUT ® = \$ 15 939

Biosimilar Mylan Ogivri ® IV = \$ 10 360

TRASTUZUMAB Activism

- 4 Feb 2016 Video linked with World Cancer Day -
https://www.youtube.com/watch?v=VI5AJa7_pDY
- 17 March 2016 UNHLP picket -
<http://www.unsgaccessmeds.org/johannesburglivestream>
- 31 March 2016 Roche picket - <https://www.youtube.com/watch?v=24JqRfXtWe8>
- 19 July 2016 International Aids Conference -
https://www.youtube.com/watch?v=mDJ_pL5hWuE
- 27 September 2016 DTI March - <https://www.youtube.com/watch?v=ZMDnyb6dh0I>
- 14 November – Tobeka dies at home.

TRASTUZUMAB Activism

- 15 November 2016 – Cancer Alliance motivates for the provision of trastuzumab in public sector.
- July 2017 – Trastuzumab is added to the **Essential Medicine List of SA for early breast cancer**
- July 2017 – Trastuzumab is recognised as a **Prescribed Minimum Benefit for early breast cancer**
- July 2019 – Motivation for speedy approval of trastuzumab biosimilars
- October – Biosimilar fact sheets and focus on cost and equity

VIVA

#ROCHE GREED KILLS

#FORTOBEKA

TOBEKA
DAKI

VIVA



STUDY SAYS

TRASTUZUMAB

**CAN BE
MADE FOR**

\$240

(PER TREATMENT COURSE)

#ROCHEGREEDKILLS

#FORTOBEKA

LENALIDOMIDE:

Generic unregistered @ US \$408/month



LENALIDOMIDE:

Registered product @ US \$6126/month





THANK YOU!

#LetsTalkAboutCancer

Together We Can – It is not beyond us

www.canceralliance.co.za